Since 2017, nine new drugs have been approved for acute myeloid leukemia (AML) in the US, dramatically changing the treatment landscape, with the condition benefiting from breakthroughs in the understanding of how gene mutations can be linked with disease, and the development of targeted medicines for an approach known as precision oncology.
AML is usually a condition of late middle age and can be rapidly fatal – the median age of diagnosis is around 67 years. The disease is characterized by genetically altered and mutated white blood cells that spread quickly into the bloodstream and lymph nodes, causing a range of symptoms including weight loss, fatigue, frequent nose bleeds and fever
